LU91315I2 - Particule similaire au virus HPV6 - Google Patents
Particule similaire au virus HPV6Info
- Publication number
- LU91315I2 LU91315I2 LU91315C LU91315C LU91315I2 LU 91315 I2 LU91315 I2 LU 91315I2 LU 91315 C LU91315 C LU 91315C LU 91315 C LU91315 C LU 91315C LU 91315 I2 LU91315 I2 LU 91315I2
- Authority
- LU
- Luxembourg
- Prior art keywords
- protein
- contg
- proteins
- vlps
- derived
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title abstract 3
- 239000002245 particle Substances 0.000 title abstract 2
- 241001631646 Papillomaviridae Species 0.000 abstract 8
- 108090000623 proteins and genes Proteins 0.000 abstract 8
- 102000004169 proteins and genes Human genes 0.000 abstract 8
- 101710132701 Protein L1 Proteins 0.000 abstract 3
- 108090000565 Capsid Proteins Proteins 0.000 abstract 2
- 102100023321 Ceruloplasmin Human genes 0.000 abstract 2
- 239000013612 plasmid Substances 0.000 abstract 2
- 108020004414 DNA Proteins 0.000 abstract 1
- 241000341655 Human papillomavirus type 16 Species 0.000 abstract 1
- 108020004511 Recombinant DNA Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20041—Use of virus, viral particle or viral elements as a vector
- C12N2710/20043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/788—Of specified organic or carbon-based composition
- Y10S977/802—Virus-based particle
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPK732291 | 1991-07-19 | ||
PCT/AU1992/000364 WO1993002184A1 (fr) | 1991-07-19 | 1992-07-20 | Vaccin contre le virus du papillome |
Publications (1)
Publication Number | Publication Date |
---|---|
LU91315I2 true LU91315I2 (fr) | 2007-04-27 |
Family
ID=3775561
Family Applications (8)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LU91318C LU91318I2 (fr) | 1991-07-19 | 2007-02-27 | Particule similaire au virus HPV 16 |
LU91317C LU91317I2 (fr) | 1991-07-19 | 2007-02-27 | Particule similaire au virus HPV6,HPV11,HPV16 et HPV18 |
LU91315C LU91315I2 (fr) | 1991-07-19 | 2007-02-27 | Particule similaire au virus HPV6 |
LU91316C LU91316I2 (fr) | 1991-07-19 | 2007-02-27 | Particule similaire au virus HPV11 |
LU91321C LU91321I2 (fr) | 1991-07-19 | 2007-03-09 | Particule similaire au virus HPV18 (gardasil, silgard) |
LU91386C LU91386I2 (fr) | 1991-07-19 | 2007-12-14 | CERVARIX - Particule similaire au virus HPV18 |
LU91385C LU91385I2 (fr) | 1991-07-19 | 2007-12-14 | CERVARIX - Particule similaire au virus HPV16 |
LU91387C LU91387I2 (fr) | 1991-07-19 | 2007-12-14 | CERVARIX - La combinaison des particules similaires au virus HPV16 et HPV18 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LU91318C LU91318I2 (fr) | 1991-07-19 | 2007-02-27 | Particule similaire au virus HPV 16 |
LU91317C LU91317I2 (fr) | 1991-07-19 | 2007-02-27 | Particule similaire au virus HPV6,HPV11,HPV16 et HPV18 |
Family Applications After (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LU91316C LU91316I2 (fr) | 1991-07-19 | 2007-02-27 | Particule similaire au virus HPV11 |
LU91321C LU91321I2 (fr) | 1991-07-19 | 2007-03-09 | Particule similaire au virus HPV18 (gardasil, silgard) |
LU91386C LU91386I2 (fr) | 1991-07-19 | 2007-12-14 | CERVARIX - Particule similaire au virus HPV18 |
LU91385C LU91385I2 (fr) | 1991-07-19 | 2007-12-14 | CERVARIX - Particule similaire au virus HPV16 |
LU91387C LU91387I2 (fr) | 1991-07-19 | 2007-12-14 | CERVARIX - La combinaison des particules similaires au virus HPV16 et HPV18 |
Country Status (17)
Country | Link |
---|---|
US (5) | US7476389B1 (fr) |
EP (5) | EP1207203A3 (fr) |
JP (3) | JP3828570B2 (fr) |
KR (1) | KR100240480B1 (fr) |
AT (3) | ATE332973T1 (fr) |
AU (1) | AU651727B2 (fr) |
CA (1) | CA2113712C (fr) |
CY (5) | CY2598B2 (fr) |
DE (11) | DE122007000023I1 (fr) |
DK (3) | DK1359156T3 (fr) |
ES (3) | ES2194839T3 (fr) |
GE (1) | GEP20084431B (fr) |
HK (1) | HK1059271A1 (fr) |
LU (8) | LU91318I2 (fr) |
NL (8) | NL300263I1 (fr) |
SG (1) | SG48769A1 (fr) |
WO (1) | WO1993002184A1 (fr) |
Families Citing this family (110)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU651727B2 (en) * | 1991-07-19 | 1994-07-28 | Csl Limited | Papilloma virus vaccine |
DE122007000098I1 (de) * | 1992-06-25 | 2008-03-27 | Papillomavirus vakzine | |
US5618536A (en) * | 1992-09-03 | 1997-04-08 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric papillomavirus-like particles |
US20020164350A1 (en) | 1992-09-03 | 2002-11-07 | Lowy Douglas R. | Chimeric papillomavirus-like particles |
US5437951A (en) * | 1992-09-03 | 1995-08-01 | The United States Of America As Represented By The Department Of Health And Human Services | Self-assembling recombinant papillomavirus capsid proteins |
US8062642B1 (en) | 1993-03-09 | 2011-11-22 | University Of Rochester | Production of papillomavirus capsid protein and virus-like particles |
US6153201A (en) * | 1993-03-09 | 2000-11-28 | University Of Rochester | Oral immunization with papillomavirus virus-like particles |
PT1618888E (pt) * | 1993-03-09 | 2011-04-08 | Univ Rochester | Produção de proteína da cápside de vírus de papiloma humano e partículas semelhantes a vírus |
AU719837B2 (en) * | 1993-03-31 | 2000-05-18 | Cancer Research Campaign Technology Limited | Pharmaceuticals based on papillomaviruses |
GB9306731D0 (en) * | 1993-03-31 | 1993-05-26 | Cancer Res Campaign Tech | Vaccines |
GB9313556D0 (en) * | 1993-07-01 | 1993-08-18 | British Tech Group | Synthetic peptides of human papillomavirus |
GB2279651A (en) * | 1993-07-01 | 1995-01-11 | British Tech Group | Synthetic peptides of human papillomavirus |
AUPM358894A0 (en) * | 1994-01-31 | 1994-02-24 | Csl Limited | Modified papilloma virus l2 protein and vlps formed therefrom |
DE4415743C2 (de) * | 1994-05-04 | 1996-10-10 | Deutsches Krebsforsch | Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen |
CA2189882C (fr) * | 1994-05-16 | 2005-09-20 | Kathrin U. Jansen | Vaccins contre le papillomavirus |
US5888516A (en) * | 1994-05-16 | 1999-03-30 | Merck & Co. Inc. | Recombinant papillomavirus vaccines |
AUPM566794A0 (en) * | 1994-05-17 | 1994-06-09 | University Of Queensland, The | Process and product |
IL113817A (en) * | 1994-06-30 | 2001-03-19 | Merck & Co Inc | Polynucleotide for vaccination against the umbilical cord virus |
AU717647B2 (en) * | 1994-10-06 | 2000-03-30 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Chimeric papillomavirus-like particles |
AU717932B2 (en) * | 1994-10-06 | 2000-04-06 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Chimeric papillomavirus-like particles |
AU2003235191B2 (en) * | 1994-10-07 | 2006-09-21 | Loyola University Of Chicago | Papilloma virus-like particles, fusion proteins as well as processes for their production |
DE4447664C2 (de) * | 1994-10-07 | 1999-04-15 | Lutz Prof Dr Gissmann | Fusionsproteine, Verfahren zu deren Herstellung sowie deren Anwendung |
DE19526752C2 (de) * | 1995-07-21 | 1997-08-07 | Lutz Prof Dr Gissmann | Hocheffiziente Bildung von Papillomavirusähnlichen Partikeln |
CA2202090C (fr) | 1994-10-07 | 2012-04-17 | Lutz Gissmann | Particules semblables au virus du papillome, proteines de fusion et leur procede de production |
AR004464A1 (es) * | 1994-11-14 | 1998-12-16 | Merck Sharp & Dohme | Un metodo para producir una proteina de capside de papilomavirus |
WO1996026277A1 (fr) * | 1995-02-24 | 1996-08-29 | Cantab Pharmaceuticals Research Limited | Polypeptides utiles comme agents immunotherapeutiques et procedes de preparation de polypeptides |
IL117459A (en) * | 1995-03-22 | 2005-11-20 | Merck & Co Inc | Dna encoding human papillomavirus type 18 |
US5820870A (en) * | 1995-03-22 | 1998-10-13 | Merck & Co., Inc. | Recombinant human papillomavirus type 18 vaccine |
GB9505784D0 (en) * | 1995-03-22 | 1995-05-10 | Lynxvale Ltd | Anti-tumour treatment |
US5840306A (en) * | 1995-03-22 | 1998-11-24 | Merck & Co., Inc. | DNA encoding human papillomavirus type 18 |
US5821087A (en) * | 1995-03-30 | 1998-10-13 | Merck & Co., Inc. | Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA |
IL117591A0 (en) * | 1995-03-30 | 1996-07-23 | Merck & Co Inc | Synthetic DNA encoding human papillomavirus type 11 L1 protein |
SE9501512D0 (sv) * | 1995-04-24 | 1995-04-24 | Euro Diagnostica Ab | Synthetic peptide-defined eptopes useful for vaccination against papillomavirus |
EP0863982B1 (fr) * | 1995-11-15 | 2004-01-21 | Merck & Co., Inc. | Particules synthetiques de type viral hpv11 |
US6908615B1 (en) | 1996-03-18 | 2005-06-21 | Merck & Co., Inc. | DNA encoding human papilloma virus type 18 |
FR2749323B1 (fr) * | 1996-06-04 | 1998-07-10 | Pasteur Merieux Serums Vacc | Pseudo-particules virales utiles en tant que vecteur de delivrance d'acide nucleique |
FR2751879B1 (fr) * | 1996-07-30 | 1998-10-30 | Transgene Sa | Composition pharmaceutique contre les tumeurs et infections a papillomavirus |
US7118754B1 (en) | 1996-07-30 | 2006-10-10 | Transgene S.A. | Pharmaceutical composition for treating papillomavirus tumors and infection |
CA2267639C (fr) * | 1996-10-04 | 2005-11-22 | Merck & Co., Inc. | Particules synthetiques de type virus vph 16 |
GB9621091D0 (en) | 1996-10-09 | 1996-11-27 | Fondation Pour Le Perfectionem | Attenuated microorganisms strains and their uses |
EP0948351B1 (fr) * | 1996-12-09 | 2004-02-25 | Merck & Co., Inc. | Particules synthetiques de nature virale de type hpv16 |
ATE341339T1 (de) * | 1996-12-20 | 2006-10-15 | Merck & Co Inc | Zusammensetzungen von rekombinanten papillomavirus vakzinen |
AU750702B2 (en) * | 1997-05-01 | 2002-07-25 | Chiron Corporation | Use of virus-like particles as adjuvants |
AU755679B2 (en) * | 1997-07-03 | 2002-12-19 | Medimmune, Llc | Homogeneous human papilloma virus capsomere containing compositions, methods for manufacture,and the use thereof as diagnostic, prophylactic or therapy |
FR2766091A1 (fr) | 1997-07-18 | 1999-01-22 | Transgene Sa | Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee |
US6962777B1 (en) * | 1997-09-05 | 2005-11-08 | Medimmune, Inc. | In vitro method for disassembly/reassembly of papillomavirus virus-like particles (vlps), homogeneous vlp and capsomere compositions produced by said methods; use thereof as vehicle for improved purification, and delivery of active agents |
US6228368B1 (en) | 1997-10-06 | 2001-05-08 | Loyola University Of Chicago | Papilloma virus capsomere formulations and method of use |
US7182947B2 (en) | 1998-02-20 | 2007-02-27 | Medigene Ag | Papillomavirus truncated L1 protein and fusion protein constructs |
US7494658B2 (en) | 1998-02-20 | 2009-02-24 | Medigene Ag | Papilloma virus truncated L1 protein and fusion protein constructs |
CA2229955C (fr) | 1998-02-20 | 2003-12-09 | Medigene Gmbh | Formulations de vaccins contenant des capsomeres de papillomavirus; methodes d'utilisation |
US20020039584A1 (en) | 1998-02-20 | 2002-04-04 | Medigene Ag | Papilloma virus capsomere vaccine formulations and methods of use |
US6926897B1 (en) | 1998-03-24 | 2005-08-09 | Medigene Aktiengesellschaft | Medicament for the avoidance or treatment of papillomavirus-specific tumour |
US6692752B1 (en) | 1999-09-08 | 2004-02-17 | Smithkline Beecham Biologicals S.A. | Methods of treating human females susceptible to HSV infection |
AUPP765398A0 (en) | 1998-12-11 | 1999-01-14 | University Of Queensland, The | Treatment of papillomavirus infections |
DE19925234A1 (de) * | 1999-06-01 | 2000-12-14 | Medigene Ag | Capsomere, stabile Capsomere, Capside, VLPs, oder CVLPs bzw. damit beladenen Zellen und ihre Verwendung in Diagnostik und Therapie |
DE19925199A1 (de) | 1999-06-01 | 2000-12-07 | Medigene Ag | Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie |
DE19925235A1 (de) | 1999-06-01 | 2000-12-07 | Medigene Ag | Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie |
GB9921146D0 (en) * | 1999-09-07 | 1999-11-10 | Smithkline Beecham Biolog | Novel composition |
GB0109297D0 (en) | 2001-04-12 | 2001-05-30 | Glaxosmithkline Biolog Sa | Vaccine |
AUPR446801A0 (en) | 2001-04-18 | 2001-05-17 | University Of Queensland, The | Novel compositions and uses therefor |
KR100785397B1 (ko) | 2001-06-28 | 2007-12-13 | 아피메즈 주식회사 | 인체 파필로마 바이러스 유사 입자를 생산하는 재조합아데노바이러스 벡터 및 자궁경부암 생백신 |
DE10137102A1 (de) | 2001-07-30 | 2003-02-27 | Deutsches Krebsforsch | Polyvalente Vakzine gegen durch Papillomaviren verursachte Erkrankungen, Verfahren zu deren Herstellung und deren Verwendung |
ATE471990T1 (de) | 2001-08-13 | 2010-07-15 | Univ Rochester | Transkutane immunisierung gegen papillomavirus mit virusähnlichen papillomaviruspartikeln |
WO2003018055A1 (fr) * | 2001-08-23 | 2003-03-06 | Merck & Co., Inc. | Vaccin mettant en oeuvre des proteines e du virus du papillome administrees par vecteur viral |
KR20030067873A (ko) * | 2002-02-08 | 2003-08-19 | 주식회사 유니크 | 솔레노이드 밸브 |
GB0206360D0 (en) | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
DK1648931T3 (da) | 2003-07-21 | 2011-03-07 | Transgene Sa | Multifunktionelle cytokiner |
US7527948B2 (en) | 2003-09-25 | 2009-05-05 | Third Wave Technologies, Inc. | Detection of HPV |
AU2005280896B2 (en) * | 2004-09-10 | 2010-08-05 | Asahi Glass Company, Limited | Vaccine for oral administration |
US8021992B2 (en) * | 2005-09-01 | 2011-09-20 | Taiwan Semiconductor Manufacturing Co., Ltd. | High aspect ratio gap fill application using high density plasma chemical vapor deposition |
TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
US8080643B2 (en) * | 2006-09-05 | 2011-12-20 | Third Wave Technologies, Inc. | HPV primers |
PT2468300T (pt) | 2006-09-26 | 2018-01-30 | Infectious Disease Res Inst | Composição para vacina contendo adjuvante sintético |
US20090181078A1 (en) | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
EP2426142A3 (fr) | 2006-10-16 | 2012-06-13 | Genelux Corporation | Souches de virus de vaccin modifiées pour une utilisation pour le diagnostic et procédé thérapeutique |
CN103550764A (zh) | 2007-03-02 | 2014-02-05 | 葛兰素史密丝克莱恩生物有限公司 | 疫苗组合物及其在刺激免疫反应中的用途 |
CN101835797A (zh) * | 2007-11-23 | 2010-09-15 | 上海泽润生物科技有限公司 | 人***状瘤病毒主要衣壳蛋白l1基因及其用途 |
CN101952436B (zh) | 2008-01-09 | 2013-03-13 | 建国大学校产学协力团 | 基于杆状病毒的疫苗 |
US9623098B2 (en) | 2008-05-26 | 2017-04-18 | Cadila Healthcare Limited | Combined measles-human papilloma vaccine |
GB0815872D0 (en) | 2008-09-01 | 2008-10-08 | Pasteur Institut | Novel method and compositions |
GB0820822D0 (en) | 2008-11-13 | 2008-12-24 | Inst Catala D Oncologia | Novel product and processes |
WO2010112533A1 (fr) * | 2009-04-03 | 2010-10-07 | Deutsches Krebsforschungszentrum | Augmentation de la production de particules analogues au papillomavirus avec un système d'expression de baculovirus modifié |
DK2437753T3 (en) | 2009-06-05 | 2016-12-19 | Infectious Disease Res Inst | Synthetic glucopyranosyl lipid adjuvants and vaccine compositions containing them |
JP5758385B2 (ja) | 2009-06-19 | 2015-08-05 | アイジェン インコーポレーテッド | 子宮頸がんワクチン |
WO2011026111A1 (fr) | 2009-08-31 | 2011-03-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Distribution par voie orale d'un vaccin au gros intestin pour induire une immunité mucosale |
EP3730943A1 (fr) | 2010-04-08 | 2020-10-28 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Analyse de cellules présentatrices d'antigène des lymphocytes b |
JP6153866B2 (ja) | 2010-05-25 | 2017-06-28 | キアゲン ガイサーズバーグ アイエヌシー. | 迅速なハイブリッド捕捉アッセイ、及び関連する戦略的に切断されたプローブ |
KR101349291B1 (ko) | 2010-08-10 | 2014-01-10 | 한국생명공학연구원 | 고초균을 이용하여 자궁경부암 백신을 제조하는 방법 |
CA2832307A1 (fr) | 2011-04-08 | 2012-10-18 | Immune Design Corp. | Compositions immunogenes et leurs procedes d'utilisation pour induire des reponses immunitaires humorales et cellulaires |
US11510875B2 (en) | 2012-02-07 | 2022-11-29 | Access To Advanced Health Institute | Adjuvant formulations comprising TLR4 agonists and methods of using the same |
EP2827891A1 (fr) | 2012-03-18 | 2015-01-28 | GlaxoSmithKline Biologicals S.A. | Procédé de vaccination contre le papillomavirus humain |
EP2850431B1 (fr) | 2012-05-16 | 2018-04-18 | Immune Design Corp. | Vaccins contre le hsv-2 |
JP6430949B2 (ja) | 2012-10-23 | 2018-11-28 | エモリー ユニバーシティ | Gm−csfとil−4のコンジュゲート、組成物、ならびにそれに関連する方法 |
CA2909221A1 (fr) | 2013-04-18 | 2014-10-23 | Immune Design Corp. | Monotherapie par gla pour une utilisation dans le traitement du cancer |
US9463198B2 (en) | 2013-06-04 | 2016-10-11 | Infectious Disease Research Institute | Compositions and methods for reducing or preventing metastasis |
KR102411781B1 (ko) | 2013-12-31 | 2022-06-22 | 인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) | 단일 바이알 백신 제형 |
WO2016149384A1 (fr) * | 2015-03-18 | 2016-09-22 | University Of Massachusetts | Compositions et vaccins à base de particules pseudovirales contre l'infection et la maladie provoquées par le virus d'epstein-barr |
KR101908438B1 (ko) * | 2016-02-05 | 2018-10-16 | (주)피앤피바이오팜 | Arsntd를 융합파트너로 이용한 수용성 및 활성형 재조합단백질의 생산방법 및 그 생산물 |
BR112018017141A2 (pt) | 2016-02-22 | 2019-01-02 | Boehringer Ingelheim Vetmedica Gmbh | método para a imobilização de biomoléculas |
IL313085A (en) | 2016-05-16 | 2024-07-01 | Access To Advanced Health Inst | Pegylated liposomes and methods of use |
IL299285A (en) | 2016-05-16 | 2023-02-01 | Access To Advanced Health Inst | Formulation containing a TLR agonist and methods of use |
AU2017273650B2 (en) | 2016-06-01 | 2022-08-18 | Access To Advanced Health Institute | Nanoalum particles containing a sizing agent |
CA3067224A1 (fr) | 2017-06-15 | 2018-12-20 | Infectious Disease Research Institute | Supports lipidiques nanostructures et emulsions stables et leurs utilisations |
CN111315406A (zh) | 2017-09-08 | 2020-06-19 | 传染病研究所 | 包括皂苷的脂质体调配物及其使用方法 |
RU2681174C1 (ru) * | 2018-07-12 | 2019-03-04 | Закрытое акционерное общество научно-производственная компания "Комбиотех" | Способ получения рекомбинантной вакцины для профилактики папилломавирусной инфекции человека, рекомбинантная вакцина |
WO2020243115A1 (fr) | 2019-05-25 | 2020-12-03 | Infectious Disease Research Institute | Composition et procédé de séchage par atomisation d'une émulsion de vaccin et d'adjuvant |
JP7017811B2 (ja) * | 2020-02-13 | 2022-02-09 | 国立研究開発法人農業・食品産業技術総合研究機構 | ウイルス様粒子及びその使用 |
US20230310323A1 (en) | 2020-09-04 | 2023-10-05 | Access To Advanced Health Institute | Co-lyophilized rna and nanostructured lipid carrier |
MX2023009456A (es) | 2021-02-11 | 2023-08-28 | Glaxosmithkline Biologicals Sa | Preparacion de la vacuna contra el vph. |
WO2024052882A1 (fr) | 2022-09-09 | 2024-03-14 | Access To Advanced Health Institute | Composition de vaccin immunogène incorporant une saponine |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2524487B1 (fr) | 1982-04-05 | 1985-11-22 | Pasteur Institut | Fragments d'adn codant pour des polypeptides contenant au moins un determinant antigenique des papillomavirus, notamment du type hpv 1a et polypeptides correspondants |
US5071757A (en) | 1986-10-06 | 1991-12-10 | Kreider John W | Methods for propagating fastidious human viruses and for producing purified suspensions thereof |
US5045447A (en) | 1989-03-15 | 1991-09-03 | Minson Anthony C | Method of producing antibodies to HPV |
NL8902301A (nl) * | 1989-09-14 | 1991-04-02 | Rijksuniversiteit | Humaan parvovirus b19 eiwitten, hun produktie en hun gebruik in diagnostische assays en vaccins. |
WO1992016638A1 (fr) * | 1991-03-14 | 1992-10-01 | 5 Prime --> 3 Prime, Inc. | Vehicules de transduction pour le transfert de l'adn a une cellule de mammifere |
AU651727B2 (en) * | 1991-07-19 | 1994-07-28 | Csl Limited | Papilloma virus vaccine |
DE122007000098I1 (de) | 1992-06-25 | 2008-03-27 | Papillomavirus vakzine | |
US5437951A (en) | 1992-09-03 | 1995-08-01 | The United States Of America As Represented By The Department Of Health And Human Services | Self-assembling recombinant papillomavirus capsid proteins |
PT1618888E (pt) | 1993-03-09 | 2011-04-08 | Univ Rochester | Produção de proteína da cápside de vírus de papiloma humano e partículas semelhantes a vírus |
-
1992
- 1992-07-20 AU AU23666/92A patent/AU651727B2/en not_active Expired
- 1992-07-20 DE DE200712000023 patent/DE122007000023I1/de active Pending
- 1992-07-20 EP EP01126938A patent/EP1207203A3/fr not_active Withdrawn
- 1992-07-20 AT AT02009841T patent/ATE332973T1/de active
- 1992-07-20 EP EP03005929A patent/EP1359156B1/fr not_active Expired - Lifetime
- 1992-07-20 DK DK03005929T patent/DK1359156T3/da active
- 1992-07-20 DK DK02009841T patent/DK1298211T3/da active
- 1992-07-20 DE DE122007000084C patent/DE122007000084I1/de active Pending
- 1992-07-20 EP EP92915973A patent/EP0595935B1/fr not_active Expired - Lifetime
- 1992-07-20 DE DE69233687T patent/DE69233687T2/de not_active Expired - Lifetime
- 1992-07-20 KR KR1019940700169A patent/KR100240480B1/ko not_active IP Right Cessation
- 1992-07-20 AT AT92915973T patent/ATE234925T1/de active
- 1992-07-20 EP EP02009841A patent/EP1298211B1/fr not_active Expired - Lifetime
- 1992-07-20 EP EP04014651A patent/EP1471147A3/fr not_active Withdrawn
- 1992-07-20 DE DE1992632967 patent/DE122007000016I1/de active Pending
- 1992-07-20 DE DE122007000085C patent/DE122007000085I1/de active Pending
- 1992-07-20 DE DE1992633639 patent/DE122007000018I1/de active Pending
- 1992-07-20 CA CA002113712A patent/CA2113712C/fr not_active Expired - Lifetime
- 1992-07-20 ES ES92915973T patent/ES2194839T3/es not_active Expired - Lifetime
- 1992-07-20 DE DE122007000086C patent/DE122007000086I1/de active Pending
- 1992-07-20 DE DE69232967T patent/DE69232967T2/de not_active Expired - Lifetime
- 1992-07-20 US US08/185,928 patent/US7476389B1/en active Active
- 1992-07-20 DK DK92915973T patent/DK0595935T3/da active
- 1992-07-20 SG SG1996001490A patent/SG48769A1/en unknown
- 1992-07-20 DE DE69233639T patent/DE69233639T2/de not_active Expired - Lifetime
- 1992-07-20 AT AT03005929T patent/ATE356142T1/de active
- 1992-07-20 DE DE200712000019 patent/DE122007000019I1/de active Pending
- 1992-07-20 WO PCT/AU1992/000364 patent/WO1993002184A1/fr active IP Right Grant
- 1992-07-20 JP JP50248693A patent/JP3828570B2/ja not_active Expired - Lifetime
- 1992-07-20 ES ES03005929T patent/ES2279020T3/es not_active Expired - Lifetime
- 1992-07-20 DE DE200712000017 patent/DE122007000017I1/de active Pending
- 1992-07-20 ES ES02009841T patent/ES2267890T3/es not_active Expired - Lifetime
-
2001
- 2001-09-07 US US09/947,372 patent/US6613557B1/en not_active Expired - Fee Related
-
2003
- 2003-08-18 JP JP2003294384A patent/JP2004000269A/ja not_active Withdrawn
- 2003-12-11 US US10/732,345 patent/US7169585B2/en not_active Expired - Fee Related
-
2004
- 2004-03-23 HK HK04102132A patent/HK1059271A1/xx not_active IP Right Cessation
-
2005
- 2005-11-24 JP JP2005339177A patent/JP4255944B2/ja not_active Expired - Lifetime
-
2006
- 2006-06-19 US US11/455,236 patent/US20070154902A1/en not_active Abandoned
-
2007
- 2007-02-21 NL NL300263C patent/NL300263I1/nl unknown
- 2007-02-21 NL NL300262C patent/NL300262I1/nl unknown
- 2007-02-21 NL NL300260C patent/NL300260I1/nl unknown
- 2007-02-21 NL NL300261C patent/NL300261I1/nl unknown
- 2007-02-27 LU LU91318C patent/LU91318I2/fr unknown
- 2007-02-27 LU LU91317C patent/LU91317I2/fr unknown
- 2007-02-27 LU LU91315C patent/LU91315I2/fr unknown
- 2007-02-27 LU LU91316C patent/LU91316I2/fr unknown
- 2007-03-07 NL NL300266C patent/NL300266I1/nl unknown
- 2007-03-09 LU LU91321C patent/LU91321I2/fr unknown
- 2007-07-20 GE GEAP200710179A patent/GEP20084431B/en unknown
- 2007-07-20 CY CY0700013A patent/CY2598B2/xx unknown
- 2007-08-06 CY CY2007015C patent/CY2007015I2/el unknown
- 2007-08-06 CY CY200700016C patent/CY2007016I2/el unknown
- 2007-12-14 LU LU91386C patent/LU91386I2/fr unknown
- 2007-12-14 NL NL300314C patent/NL300314I2/nl unknown
- 2007-12-14 CY CY2007030C patent/CY2007030I2/el unknown
- 2007-12-14 LU LU91385C patent/LU91385I2/fr unknown
- 2007-12-14 NL NL300313C patent/NL300313I1/nl unknown
- 2007-12-14 CY CY2007034C patent/CY2007034I1/el unknown
- 2007-12-14 NL NL300312C patent/NL300312I1/nl unknown
- 2007-12-14 LU LU91387C patent/LU91387I2/fr unknown
-
2008
- 2008-12-22 US US12/318,138 patent/US7939082B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LU91315I2 (fr) | Particule similaire au virus HPV6 | |
NL300323I1 (nl) | Op papillomavirus lijkende deeltjes, fusie-eiwitten alsook werkwijze | |
DE05075369T1 (de) | Herstellung von menschlichem Papilloma-Virus-Capsid-Protein und virusähnlichen Teilchen | |
CA2339324A1 (fr) | Systeme de distribution de proteine utilisant des particules humaines de type papillomavirus |